Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin’s lymphoma. The patent, expected to grant with exclusivity … Continue reading →

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by … Continue reading →

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer … Continue reading →

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, recently reported an encouraging clinical outcome in its Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer … Continue reading →

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. … Continue reading →